

July 11, 2026

To,
The Secretary,
Listing Department
Bombay Stock Exchange Ltd
Phiroze Jeejeebhoy Towers,
Street, Mumbai – 400 001

Reference: Scrip Code: 524723/ ISIN: INE491D01017

Subject: Outcome of Meeting of Board of Directors of Arvaya Healthcare Limited (Formerly Known as Bijoy Hans Limited) (“the Company”) in accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“Listing Regulation”)

Respected Authorities,

Pursuant to the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of the Board of Directors of the Arvaya Healthcare Limited (Formerly Known as Bijoy Hans Limited) (“Company”) held today i.e. **Saturday, July 11, 2026** through video conferencing/other audio-visual has inter alia, considered and approved the following amongst other items of agenda:

1. **Approved the acquisition of 100% of equity shares (1,84,374 Equity Shares of Re. 10/- each) of M/s Sushodha Institute of Gastroenterology Private Limited (“SIGPL”)**

The board approved the Acquisition of 100% equity shares [1,84,374 (One Lakh Eighty Four Thousand Three Hundred and Seventy Four)] of Sushodha Institute of Gastroenterology Private Limited for a total purchase consideration of Rs. 15,48,74,160/- (Rupees Fifteen Crore Forty Eight Lakh Seventy Four Thousand One Hundred and Sixty Only) at a price of Rs. 840/- (Rupees Eight Hundred and Forty Only) per equity share. (Purchase Consideration).

The Purchase Consideration payable shall be discharged by way of issue and allotment of upto 38,71,854 (Thirty Eight Lakh Seventy One Thousand Eight Hundred and Fifty Four) fully paid-up equity shares of the Company having face value of Rs. 10/- (Rupees Ten Only) each at a price of Rs. 40/- (Rupees Forty Only) per equity share (including a premium of Rs. 30/- per share).

The proposed transaction is being done at arm’s length, taking into account the valuation report issued by Mr. Shreyas Bharat Ohara, Registered Valuer (Registration No. IBBI/RV/06/2019/11474), in accordance with the applicable laws. The completion of the acquisition is subject to customary conditions such as receipt of shareholders’ approval and other regulatory approvals, if any required

Details regarding the proposed acquisitions, as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (“SEBI Circular”), is enclosed herewith as **Annexure-A**.

2. Considered and approved the issuance of the equity shares by way of preferential issue on private placement basis (“Preferential Issue”):

Subject to the approval of members of the Company and such other regulatory/governmental authorities as may be required, the Board has approved the issuance of the equity shares by way of a preferential allotment on a private placement basis, upto 38,71,854 (Thirty Eight Lakh Seventy One Thousand Eight Hundred and Fifty Four) fully paid-up equity shares of the Company having a face value of ₹ 10/- (Rupees Ten Only) each at a price of ₹ 40/- (Rupees Forty Only) per equity share, including a premium of ₹ 30/- per share, at a price which shall not be less than floor price as determined in accordance with the provisions of Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”), to the shareholder of Sushodha Institute of Gastroenterology Private Limited (“SIG”) for consideration other than cash being the acquisition of 100% (1,84,374 equity shares of SIGPL for an aggregate consideration ₹ 15,48,74,160/- (Rupees Fifteen Crore Forty Eight Lakh Seventy Four Thousand One Hundred and Sixty Only) (being discharged by way of issue of the Shares)

The details as required to be disclosed under Regulation 30 of the Listing Regulations read with SEBI Circular, is enclosed herewith as **Annexure-B**.

3. The Board of Directors has approved the constitution of a Rights Issue Committee to, inter alia, undertake all necessary actions in connection with the proposed Rights Issue, including determining the terms and conditions of the Rights Issue and all other related matters, in accordance with the applicable provisions of law.

The Rights Issue Committee shall comprise the following members:

1. Mr. Kaushal Uttam Shah – Chairman of the Committee.
2. Mr. Salil Shetty – Member of the Committee.
3. Mr. Rahul Ravindra Mayur – Member of the Committee.

The Board has delegated to the Rights Issue Committee such powers and authority as may be necessary to give effect to the proposed Rights Issue, including the authority to do all such acts, deeds, matters and things as may be required in connection therewith, subject to applicable laws and regulatory requirements.

4. Approved the fund raising by way of the Rights Issue of Specified Securities, to eligible equity shareholders of the Company as on the record date (to be notified later), for a maximum amount not exceeding Rs. 210 Crores (Rupees Two Hundred Ten Crores Only) (the “Issue”), subject to applicable laws. The relevant details pursuant to Listing Regulations and other applicable circulars, are enclosed as **Annexure C**.
5. Approved appointment of Mr. Kaushal Shah, Managing Director of the Company as a Non-Executive Director of the SMCV Management Services Private Limited.
6. Approved appointment of Mr. Ranganath Abhiram, Chief Financial Officer of the Company as a Non-Executive Director of the SMCV Management Services Private Limited.
7. Change in situation of registered office from one state (Assam) to another (Maharashtra) i.e. from Nirvana Co Working spaces, Mezzanine Floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam, India, 781005 to Unit No 408 Third floor Royal Miraj Arcade, Laxmi Market Miraj Shrikant Chowk Sangli, Miraj, Maharashtra, India, 416410 subject to necessary approvals in accordance with the provisions of Companies Act, 2013 and rules made thereunder.

8. The Board of Directors considered and approved to conduct of a postal ballot process in accordance with Section 110 and other applicable provisions of the Companies Act, 2013, and the Companies (Management and Administration) Rules, 2014, and authorized the Directors/Company Secretary to take all necessary actions in connection with the postal ballot process.
9. The Board of Directors appointed Mr. Chinmay Mohan Lele, Practicing Company Secretary (Membership No. F-12351 / COP No. 28362), as the Scrutinizer to oversee the Postal Ballot process of the Company and to submit a report thereon in a fair and transparent manner.
10. Considered and fixed cut-off date for E-voting & dispatch of Postal Ballot Notice and E-voting period as decided below:

Sr. No.	Particulars	Date
1	Date of Dispatch of Postal Ballot Notice	Monday, 13 th July, 2026
2	Cut-off date for E-voting	Friday, 10 th July, 2026
3	E-Voting Start Date and Time	Wednesday, 15 th July, 2026
4	E-Voting End Date and Time	Thursday, 13 th August, 2026

The meeting of Board of Directors of the Company commenced at 12.00 noon and concluded at 2.30 p.m.

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For and On Behalf Of
Arvaya Healthcare Limited
(Formerly Known as Bijoy Hans Limited)

Kaushal Uttam Shah
Managing Director
DIN: 02175130
Place: Sangli

Encl: as above

ANNEXURE A

Pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Circular dated September 9, 2015

Sr. No.	Particulars	Sushodha Institute of Gastroenterology Private Limited												
1.	Name of the target entity, details in brief such as size turnover, etc.	<p>Sushodha Institute of Gastroenterology Private Limited</p> <p>SIGPL incorporated on 17th June, 2016 is engaged in the business of in providing specialized healthcare services with a focus on gastroenterology and digestive diseases. The company operates a specialty hospital/clinical facility offering diagnosis, medical and surgical treatment, endoscopy, gastrointestinal care and allied healthcare services.</p> <p>Sushodha Institute of Gastroenterology (SIGE) is an exclusive super-specialty gastroenterology hospital at Shivamogga, covering both medical and surgical gastroenterology services. Sushodha Hospital is one of a kind in the region to provide entire subspecialties of gastroenterology under one roof.</p> <p>Country of presence: India</p> <p>Financial Figures of last 3 years</p> <table border="1"> <thead> <tr> <th>History of last 3 years turnover</th> <th>Year Description</th> <th>Amount of turnover(in Cr)</th> </tr> </thead> <tbody> <tr> <td>1st previous year turnover</td> <td>2023-24</td> <td>6.36</td> </tr> <tr> <td>2ndst previous year turnover</td> <td>2024-25</td> <td>7.78</td> </tr> <tr> <td>3rdst previous year turnover</td> <td>2025-26</td> <td>8.99</td> </tr> </tbody> </table>	History of last 3 years turnover	Year Description	Amount of turnover(in Cr)	1st previous year turnover	2023-24	6.36	2ndst previous year turnover	2024-25	7.78	3rdst previous year turnover	2025-26	8.99
History of last 3 years turnover	Year Description	Amount of turnover(in Cr)												
1st previous year turnover	2023-24	6.36												
2ndst previous year turnover	2024-25	7.78												
3rdst previous year turnover	2025-26	8.99												
2.	Whether the acquisition/investment would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>Yes. Mr. Bidari Kotresh Anilkumar, Shareholder and Additional Director of SIGPL, and he is also Shareholder & Additional Director of the Company i.e. Arvaya Healthcare Limited and Mr. Dhanaji Dattatray Jadhav is a Shareholder of the SIGPL & Company i.e. Arvaya Healthcare Limited being a related party under Section 2(76) of the Companies Act, 2013 and Regulation 2(1) (zb) of the Listing Regulations.</p> <p>The proposed transaction is being done at arm's length, taking into account the valuation report issued by Mr. Shreyas Bharat Ohara, IBBI Registered Valuer-Securities and Financial Assets, Registered Valuer (IBBI Registration No.: IBBI/RV/06/2019/11474), in accordance with the applicable laws and subject to</p>												

		receipt of approval from shareholders												
3	Industry to which the entity being acquired/invested belongs	Healthcare and Hospital management services												
4	Objects and effects of acquisition/investment (including but not limited to, disclosure of reasons for acquisition/investment of target entity, if its business is outside the main line of business of the listed entity)	The acquisition will enable the company to: <ul style="list-style-type: none"> • Achieve business synergies and operational efficiencies; • Expand its hospital and diagnostic footprint in key markets; • Enhance revenue streams through integrated healthcare offerings; and • Strengthen its balance sheet by acquiring an established and profitable healthcare entity 												
5	Brief details of any governmental or regulatory approvals required for the acquisition/investment	No governmental or regulatory approvals required for the acquisition.												
6	Indicative time period for completion of the acquisition/investment	The transaction is expected to be completed within 12 months, subject to completion of condition precedents as detailed in the SPSSA and other regulatory approvals.												
7	Nature of consideration whether cash consideration or share swap and details of the same	Swapping of Shares												
8	Cost of acquisition/investment or the price at which the shares are acquired.	₹ 15,48,74,160/- (Rupees Fifteen Crore Forty Eight Lakh Seventy Four Thousand One Hundred and Sixty Only),												
9	Percentage of shareholding/control acquired and /or number of shares acquired.	The Company shall acquire 100% equity stake in SIGPL.												
10	Brief background about the entity acquired/invested in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired/invested entity has presence and any other significant information (in brief)	<p>SIGPL incorporated on 17th June, 2016 is engaged in the business of in providing specialized healthcare services with a focus on gastroenterology and digestive diseases. The company operates a specialty hospital/clinical facility offering diagnosis, medical and surgical treatment, endoscopy, gastrointestinal care and allied healthcare services.</p> <p>Sushodha Institute of Gastroenterology (SIGE) is an exclusive super-specialty gastroenterology hospital at Shivamogga, covering both medical and surgical gastroenterology services. Sushodha Hospital is one of a kind in the region to provide entire subspecialties of gastroenterology under one roof.</p> <p>Country of presence: India</p> <p>Financial Figures of last 3 years</p> <table border="1"> <thead> <tr> <th>History of last 3 years turnover</th> <th>Year Description</th> <th>Amount of turnover(in Cr)</th> </tr> </thead> <tbody> <tr> <td>1st previous year turnover</td> <td>2023-24</td> <td>6.36</td> </tr> <tr> <td>2ndst previous year turnover</td> <td>2024-25</td> <td>7.78</td> </tr> <tr> <td>3rdst previous year turnover</td> <td>2025-26</td> <td>8.99</td> </tr> </tbody> </table>	History of last 3 years turnover	Year Description	Amount of turnover(in Cr)	1st previous year turnover	2023-24	6.36	2ndst previous year turnover	2024-25	7.78	3rdst previous year turnover	2025-26	8.99
History of last 3 years turnover	Year Description	Amount of turnover(in Cr)												
1st previous year turnover	2023-24	6.36												
2ndst previous year turnover	2024-25	7.78												
3rdst previous year turnover	2025-26	8.99												

ANNEXURE B - Sushodha Institute of Gastroenterology Private Limited

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular dated September 9, 2015

Sr. No.	Particulars	Details
1.	Type of Securities proposed to be issued	Equity Shares of face value Rs. 10/- (Rupees Ten Only) per share.
2.	Type of Issuance	Preferential Issue on a private placement basis for consideration other than cash.
3.	Total Number of Securities proposed to be issued and the Total Amount for which the Securities will be issued (approximately)	38,71,854 (Thirty Eight Lakh Seventy One Thousand Eight Hundred and Fifty Four) Equity Shares of the Company of face value of ₹ 10/- (Rupees Ten each), fully paid-up at an Issue Price of ₹ 40/- per Equity Share (Rupees Forty Only) including a premium of ₹ 30/- (Rupees Thirty Only) per Equity Share aggregating to ₹ 15,48,74,160/- (Rupees Fifteen Crore Forty Eight Lakh Seventy Four Thousand One Hundred and Sixty Only) for consideration other than cash, on Preferential Basis
4	Details to be furnished in case of preferential issue	
(a)	NO. of investor & Name of the investors	Forty Seven As detailed the Annexure-B1 (List of proposed allottees of Sushodha Institute of Gastroenterology Private Limited)
(b)	Issue Price	Issue Price of ₹ 40/- per Equity Share (Rupees Forty Only) including a premium of ₹ 30/- (Rupees Thirty Only) per Equity Share, as determined under Chapter V of SEBI ICDR Regulations, arrived through valuation report issued by Registered Valuer.
(c)	In case of convertible intimation on the conversion of securities or on lapse of the tenure of the instrument	Not Applicable
(d)	Any cancellation or termination of proposal for issuance of securities Including reasons thereof	Not Applicable

ANNEXURE- B 1

(List of proposed allottees of Sushodha Institute of Gastroenterology Private Limited)

Sr. no	Name of Proposed Allottees (Sushodha Institute of Gastroenterology Private Limited)	Category	No. of Shares of Arvaya Healthcare Limited (Formerly Known as Bijoy Hans Limited) proposed to be allotted for the acquisition of SIGPL Shares
1	J K Pradeepkumar	Non-Promoter	1328124
2	B K Anilkumar	Additional Director & Shareholder Non- Promoter	591129
3	Ambika S Chiniwalar	Non-Promoter	25305
4	Arun Kumar Jeedi	Non-Promoter	63273
5	Chandrashekhar Byadgi	Non-Promoter	25305
6	Kavita Bhairi	Non-Promoter	25305
7	Rudresh Tabali	Non-Promoter	63273
8	Saroja S Bhairi	Non-Promoter	75936
9	SL Manasa	Non-Promoter	63273
10	Jyoti Jambaladinni	Non-Promoter	25305
11	Mankani Navin Hanamanthreddi	Non-Promoter	12663
12	Mohan Vijapur	Non-Promoter	25305
13	N Goravar	Non-Promoter	25305
14	Padmashree K	Non-Promoter	27846
15	Parithosh Jayanthi	Non-Promoter	88578
16	R Manikya	Non-Promoter	31626
17	Sapan D S	Non-Promoter	12663
18	Reena Biradar	Non-Promoter	25305
19	Rajeshwari M	Non-Promoter	25305
20	Ravi Prasad	Non-Promoter	63273
21	Shrikant S Ramanagoudar	Non-Promoter	12663
22	Vinay Pawar	Non-Promoter	31626
23	Sneha Vikranth Dharamshi	Non-Promoter	37968
24	Sowmya G S	Non-Promoter	63273
25	Vishwanath M Patil	Non-Promoter	12663
26	Vishwas D Pai	Non-Promoter	63273
27	Virendra Bhasme	Non-Promoter	31626
28	Vishwanath S	Non-Promoter	25305
29	Jayaraj Patil	Non-Promoter	50610
30	Ashwin Shrigopal Marda	Non-Promoter	5061
31	Marda Abhishek Shrigopal	Non-Promoter	5061
32	Pratyush Yogesh Goyal	Non-Promoter	12663
33	Yogesh Goyal (HUF)	Non-Promoter	37968
34	Vinod Nawandhar	Non-Promoter	63273

ARVAYA HEALTHCARE LIMITED

(Formerly Known as Bijoy Hans Limited)

CIN:L86100AS1985PLC002323



Sr. no	Name of Proposed Allottees (Sushodha Institute of Gastroenterology Private Limited)	Category	No. of Shares of Arvaya Healthcare Limited (Formerly Known as Bijoy Hans Limited) proposed to be allotted for the acquisition of SIGPL Shares
35	Harjiv Singh Swani	Non-Promoter	25305
36	Rajesh Udhaudas Moorjani	Non-Promoter	63273
37	AKB Enterprises	Non-Promoter	101241
38	Gopalkrishnan Vijayaraghavan	Non-Promoter	12663
39	Sanjeev V Chintamani	Non-Promoter	63273
40	Dhanaji Dattatray Jadhav	Shareholder & Non-Promoter	151851
41	Charu Bansal	Non-Promoter	101241
42	Yogesh Laxman Rajhans	Non-Promoter	70875
43	Jalpa Darshan Shah	Non-Promoter	70875
44	Anandrao Nanaso Ghadge	Non-Promoter	20244
45	Priyadarshini R.E.	Non-Promoter	25305
46	Ramappa Huchchappa Doddamani	Non-Promoter	50610
47	Srinivasa Appasani	Non-Promoter	37968
TOTAL			38,71,854

Regd. Off.: Nirvana Co Working spaces, Mezzanine Floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Gmc, Kamrup- 781005, Assam, India

E-mail : compliance@arvayahealth.com • Mo. +91 70666 70199

ANNEXURE C

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular dated September 9, 2015

Sr. No.	Particulars	Details
1.	Type of Securities proposed to be issued	Fully/Partly Paid-up Equity shares
2.	Type of Issuance	Rights Issue
3.	Total Number of Securities proposed to be issued and the Total Amount for which the Securities will be issued (approximately)	Amount not exceeding Rs. 210 Crores, subject to applicable laws. The Rights Issue Committee constituted to decide and finalize the type of instrument, issue price, no. of Rights shares to be issued and other terms and conditions of the issue, including but not limiting to deciding the rights entitlement ratio, record date, timing, terms and schedule of payment etc. from time to time.
4	Details to be furnished in case of preferential issue	
(a)	NO. of investor & Name of the investors	Not Applicable
(b)	Issue Price	Not Applicable
(c)	In case of convertible intimation on the conversion of securities or on lapse of the tenure of the instrument	Not Applicable
(d)	Any cancellation or termination of proposal for issuance of securities Including reasons thereof	Not Applicable